Combination Therapy with Topical Minoxidil and Nano-Microneedle-Assisted FGF for MAA

0
0
0

Combination Therapy with Topical Minoxidil and Nano-Microneedle-Assisted Fibroblast Growth Factor for Male Androgenetic Alopecia: A Randomized Controlled Trial in Chinese Patients

Male androgenetic alopecia (MAA), characterized by progressive hair follicle miniaturization and hair loss, is the most prevalent form of hair loss in men. While treatments such as oral medications, topical agents, and laser therapies exist, only topical minoxidil is approved by the U.S. Food and Drug Administration for this condition. Recent studies suggest that fibroblast growth factors (FGFs), particularly basic FGF (bFGF), may promote hair follicle growth in preclinical models, offering a novel therapeutic avenue. Nano-microneedles, a transdermal drug delivery technology, enhance the penetration of topical agents by 10- to 20-fold, further improving their efficacy. This randomized controlled trial evaluated the safety and efficacy of combining topical minoxidil with nano-microneedle-assisted FGF for treating MAA, comparing it to monotherapy with either agent or saline.

Study Design and Methodology

The trial enrolled 40 Chinese male patients aged 22–50 years with confirmed MAA. Participants had no history of hair cycle-affecting treatments in the preceding six months and were free of other hair disorders or systemic diseases. Using a random number table, patients were allocated to four groups of 10 each:

  • Group S (Saline control): Weekly application of saline via nano-microneedle.
  • Group M (Minoxidil monotherapy): Twice-daily 5% minoxidil solution with scalp massage.
  • Group F (FGF monotherapy): Weekly nano-microneedle-assisted FGF application.
  • Group MF (Combination therapy): Combined 5% minoxidil (twice daily) and weekly FGF with nano-microneedles.

Treatments spanned 16 weeks, with monthly evaluations for safety and efficacy. Standardized global photographs and trichoscopic measurements were obtained using a digital camera (Nikon D40s) and hair microscope (CBS-1717). Hair density (hairs/cm²), hair diameter (μm), and follicular unit density (follicles/cm²) were quantified in a 10-mm² marked scalp area. Subjective evaluations by blinded dermatologists and participants utilized a six-point scale (-1 to 4), with higher scores indicating greater improvement. Adverse events and procedural pain (rated 0–10) were monitored.

Key Findings

Hair Density and Diameter Improvements

  • Minoxidil Monotherapy (Group M):

    • Hair density increased from 104.12 ± 30.54/cm² to 129.07 ± 27.52/cm² (P < 0.05).
    • Hair diameter improved from 70.00 ± 16.33 μm to 77.00 ± 13.37 μm (P < 0.05).

  • FGF Monotherapy (Group F):

    • Hair density rose from 91.53 ± 37.98/cm² to 118.88 ± 41.41/cm² (P < 0.05).
    • Follicular unit density increased from 109.20 ± 32.80/cm² to 139.95 ± 24.48/cm² (P < 0.05).

  • Combination Therapy (Group MF):

    • Superior outcomes were observed: Hair density surged from 100.92 ± 27.79/cm² to 155.01 ± 24.64/cm² (P < 0.05 vs. monotherapies).
    • Hair diameter improved from 63.00 ± 16.36 μm to 70.00 ± 15.63 μm (P < 0.05).
    • Follicular unit density increased from 109.93 ± 19.80/cm² to 130.02 ± 15.65/cm² (P < 0.05).

Group S (saline) showed no significant changes, confirming that nano-microneedle mechanical stimulation alone did not drive hair growth.

Subjective Evaluations

Both investigators and participants reported marked improvements:

  • Investigator assessments: 70% (21/30) noted improvements in Groups M, F, and MF.
  • Participant assessments: 90% (27/30) reported benefits in active treatment groups.
  • The Kruskal-Wallis H-test revealed significant intergroup differences (P < 0.05), though pairwise comparisons among Groups M, F, and MF lacked statistical significance, likely due to small sample sizes.

Safety and Tolerability

No severe adverse events occurred. Three participants experienced transient mild erythema (resolved within 24 hours). Procedural pain from nano-microneedles was minimal (tolerable across groups), with no discontinuations due to discomfort.

Mechanistic Insights and Synergistic Effects

Minoxidil, a vasodilator, prolongs the anagen phase and enlarges hair follicles, increasing hair shaft diameter. FGF promotes follicle regeneration and density via pro-angiogenic and anti-apoptotic mechanisms. Nano-microneedles enhance FGF delivery to deeper dermal layers, optimizing bioavailability. The combination therapy’s superiority likely stems from complementary mechanisms: minoxidil stabilizes hair growth, while FGF stimulates follicular regeneration.

Clinical Implications and Future Directions

This trial demonstrates that combining nano-microneedle-assisted FGF with minoxidil offers a safe, synergistic approach for MAA. While monotherapies improve specific parameters (minoxidil enhances diameter; FGF boosts density), their combination addresses multiple facets of hair loss. Limitations include the short 16-week duration and small cohort, warranting larger, longer-term studies to confirm durability and safety. Further research should explore optimal dosing regimens, cost-effectiveness, and broader demographic applicability.

DOI: doi.org/10.1097/CM9.0000000000001195

Was this helpful?

0 / 0